NCT01503632 2026-04-08
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Children's Oncology Group
Phase 3 Completed
Clinical Trials
365 trialsNCT04102020 2026-04-08
VIALE-M
AbbVie
Phase 3 Completed
NCT00931645 2026-04-02
Auto-LLC 2001
University Hospital, Caen
Phase 3 Completed
NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT04285567 2026-03-03
CRISTALLO
Hoffmann-La Roche
Phase 3 Completed
NCT02730299 2026-02-25
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Phase 3 Completed
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT03594149 2026-01-02
AZABAC
Centre Henri Becquerel
Phase 3 Completed
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT04620369 2025-12-03
Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy
Mayo Clinic
Phase 3 Completed
NCT04008706 2025-12-01
ASSURE
AstraZeneca
Phase 3 Completed
NCT02242942 2025-11-06
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT03268954 2025-10-29
PANTHER
Takeda
Phase 3 Completed
NCT03136445 2025-10-28
TREATT
NHS Blood and Transplant
Phase 3 Completed
NCT04666259 2025-10-16
AIM4CML
Novartis
Phase 3 Completed
NCT04502030 2025-10-03
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Octapharma
Phase 3 Completed
NCT02201459 2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3 Completed
NCT03069352 2025-09-30
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT02752035 2025-09-12
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Astellas Pharma Inc
Phase 3 Completed
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT04260698 2025-07-02
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Gamida Cell ltd
Phase 3 Completed
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT00408005 2025-04-20
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT03106779 2025-04-08
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
Phase 3 Completed
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT01437787 2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3 Completed
NCT02688140 2025-02-26
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT03125070 2025-01-29
INSPIRE
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02997202 2025-01-17
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 3 Completed
NCT00769522 2024-12-31
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 3 Completed
NCT02863718 2024-12-30
CLL12
German CLL Study Group
Phase 3 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT04233034 2024-11-27
CLVer
Jaeb Center for Health Research
Phase 3 Completed
NCT01503515 2024-10-16
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Children's Oncology Group
Phase 3 Completed
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT01724346 2024-09-19
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Pharmacyclics LLC.
Phase 3 Completed
NCT03078855 2024-09-04
ILyAD
University of Rochester
Phase 3 Completed
NCT02920008 2024-08-28
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT02348489 2024-08-27
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT02907359 2024-08-27
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03306264 2024-08-27
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT00991211 2024-08-22
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
Phase 3 Completed
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT05290545 2024-08-13
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 3 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed